Navigation Links
The Leukemia & Lymphoma Society is Encouraged by Promising News for Myeloma Patients
Date:9/18/2007

WHITE PLAINS, N.Y., Sept. 18 /PRNewswire/ -- Millennium Pharmaceuticals and Johnson & Johnson have reported that an interim analysis of a large, randomized, international Phase III trial comparing melphalan-prednisone (MP) with MP in combination with Velcade(R) (bortezomib) showed that the patients treated on the Velcade arm did better. These patients, who are not eligible for a stem cell transplant, experienced statistically significant benefit in terms of time-to-disease progression, complete response rate, progression-free survival and overall survival. Patients treated on the MP arm of the trial have the opportunity to switch over to the Velcade arm.

Detailed results from this trial will be presented at the American Society of Hematology annual meeting in early December.

"This is extremely encouraging news for myeloma patients," said Bart Kamen, M.D., Ph.D., the Society's chief medical officer. "However, while these results are very exciting, the Society reminds patients not to make any changes in their treatment regimen without speaking to their doctor first."

About The Leukemia & Lymphoma Society

The Leukemia & Lymphoma Society, headquartered in White Plains, NY, with 68 chapters in the United States and Canada, is the world's largest voluntary health organization dedicated to funding blood cancer research and providing education and patient services. The Society's mission: Cure leukemia, lymphoma, Hodgkin's disease and myeloma, and improve the quality of life of patients and their families. Since its founding in 1949, the Society has invested more than $550 million in research specifically targeting leukemia, lymphoma and myeloma. Last year alone, the Society made 5.1 million contacts with patients, caregivers and healthcare professionals.

For more information about blood cancer, visit http://www.LLS.org or call the Society's Information Resource Center (IRC), a call center st
'/>"/>

SOURCE The Leukemia & Lymphoma Society
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Nuvelo Announces Publication of Preclinical Study Results Demonstrating the Potential of NTB-A as a New Target for Leukemia and Lymphomas
2. Dasatinib Shows High Early Response Rate as First Treatment for Chronic Myelogenous Leukemia, M. D. Anderson Researchers Report
3. Promising Results with Epratuzumab and Chemotherapy in Children with Acute Lymphoblastic Leukemia
4. ZymoGenetics Reports Results From Atacicept Phase 1b Clinical Trial in B-Cell Chronic Lymphocytic Leukemia
5. Major Gene Study Uncovers Secrets of Leukemia
6. Pixantrone Combination Therapy for First-line Treatment of Aggressive Non-Hodgkins Lymphoma Results in Reduction in Severe Toxicities Including Heart Damage When Compared to Doxorubicin-based Therapy
7. Based on Up to 6 Years of Follow-Up, Biovest Announces Favorable Interim Blinded Data for Fast-Tracked Pivotal Phase 3 Clinical Trial of BiovaxID Anti-Cancer Vaccine for Non-Hodgkins Lymphoma
8. Fractionated Radioimmunotherapy With (90)Y-epratuzumab in Non-Hodgkins Lymphoma Appears Safe and Active in a Phase I/II Study
9. Favrille Announces Data From Phase 2 Clinical Trial of FavId for Indolent B-Cell Non-Hodgkins Lymphoma in Europe
10. Gloucester Pharmaceuticals Reports Positive Interim Phase II Data on Romidepsin for T-Cell Lymphomas at the 2007 American Society of Clinical Oncology Annual Meeting
11. Ontak (denileukin diftitox) Achieves 49.1% Overall Response Rate in Phase III Trial of Cutaneous T-Cell Lymphoma (CTCL)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/30/2014)...  Decision Resources Group finds that the Asia Pacific ... China , India , ... through 2023. Dental implant procedure volumes will grow as physicians are ... Other key findings from Decision Resources Group,s coverage of the ... , Dental implant penetration: Penetration of dental implants among the ...
(Date:9/30/2014)... , Sept. 30, 2014   Easy Breathe ... destination , today announced that it now offers the ... AirSense CPAPs are the first sleep apnea therapy devices ... simple and easy to track and share real-time data ... effectiveness of their CPAP therapy.  In addition, the internal ...
(Date:9/30/2014)... , N.J. and NEW BRUNSWICK, N.J., Sept. 30, 2014 ... agreement that allows Kessler Foundation and New Jersey ... biomedical research, education and patient care programs has ... and chief executive officer of Kessler Foundation and ... Jersey Health Foundation. "The experience of ...
Breaking Medicine Technology:Asia Pacific Dental Implant Market Will Grow at a Strong Rate Through 2023 2Asia Pacific Dental Implant Market Will Grow at a Strong Rate Through 2023 3Easy Breathe Now Offers World's First "Smart" CPAP Device to Treat Sleep Apnea 2Easy Breathe Now Offers World's First "Smart" CPAP Device to Treat Sleep Apnea 3Easy Breathe Now Offers World's First "Smart" CPAP Device to Treat Sleep Apnea 4Kessler Foundation Partners with New Jersey Health Foundation To Start Innovative Companies To Change the Lives of People with Disabilities 2
... Leading academic and industry specialists ... discuss the challenges that could see R&D grind to a ... Selecting and screening the correct polymorphs and ensuring ... effective way has never been more vital. According to George ...
... Ontario, Canada, Oct. 27, 2011 Valeant Pharmaceuticals International, Inc. ... of 8,523,517 additional common shares of Afexa Life Sciences Inc. ... of the offer by its wholly-owned subsidiary 1625907 Alberta Ltd. ... of Afexa. As all of the conditions to the offer ...
Cached Medicine Technology:Pharma Industry Unites With Academia to Tackle Ongoing Problem 2Valeant Announces Take-Up of Additional Afexa Shares and Special Meeting of Shareholders of Afexa to Approve Its Privatization 2Valeant Announces Take-Up of Additional Afexa Shares and Special Meeting of Shareholders of Afexa to Approve Its Privatization 3
(Date:9/30/2014)... emissions will reduce other harmful air pollution and ... new study released today. The research shows that, ... final Clean Power Plan, the power plant standards ... and hundreds of heart attacks in the United ... Co-benefits of Carbon Standards for Existing Power Plants, ...
(Date:9/30/2014)... University] Autism is no stranger to the children ... nation is access to clinical services, including reliable diagnosis ... for example, validated for use in Swahili, a major ... however, researchers at Brown University and the University of ... they implemented at two sites in the country and ...
(Date:9/30/2014)... Shrewsbury, NJ (PRWEB) September 30, 2014 ... health and wellness, is opening another new medical specialty ... group. IMA Cardiology will be located within ... Dr. Ziad Abbud and Dr. Isaac Tawfik of American ... Neptune, N.J. The new practice will offer Integrated Medicine ...
(Date:9/30/2014)... Glycodrive , one of the newest ... maximize lean, strong muscle growth with a proprietary blend ... has caught the attention of Shane Michaels, prompting an ... is to help the body use carbohydrates in a ... essential in the muscle-building process, and Glycodrive makes them ...
(Date:9/30/2014)... Angeles, CA (PRWEB) September 30, 2014 ... surgery providers in Turkey has gone up more than ... growth. The medical tourism company also reported total revenue ... October 2012. , The company’s professional strategy has allowed ... Turkey — ultimately designed for patient comfort and privacy ...
Breaking Medicine News(10 mins):Health News:Power plant standards could save thousands of US lives every year 2Health News:Power plant standards could save thousands of US lives every year 3Health News:New diagnostic approach for autism in Tanzania 2Health News:New diagnostic approach for autism in Tanzania 3Health News:New diagnostic approach for autism in Tanzania 4Health News:Integrated Medicine Alliance Announces New Cardiology Practice 2Health News:Glycodrive Review Exposes Blue Star Nutraceutical’s Supplement for Leaner, Stronger Muscles 2Health News:VisitandCare.com Announces Record Demand for Plastic Surgery in Turkey 2Health News:VisitandCare.com Announces Record Demand for Plastic Surgery in Turkey 3Health News:VisitandCare.com Announces Record Demand for Plastic Surgery in Turkey 4
... Be Celebrity Host of Show at Nassau Coliseum, NEW ... the first of its 2009 Concert Series -- a Valentine,s ... Research,Foundation., The show will be held on February 14th, ... on sale Monday, November 10th at 10am,through Ticketmaster.com or by ...
... at National Health Science Summit, DALLAS, Nov. ... prevention, today announced Dr. Valentin Fuster, director of,Mount ... Prevention Prize.,The Prize was presented to Dr. Fuster ... National Health Science Summit held on,November 7, 2008 ...
... 7 /PRNewswire-FirstCall/ - Transition Therapeutics Inc.,("Transition" or the "Company") ... call on Monday, November 10, 2008 at 4:30 P.M. ... Dr. Tony Cruz, Chairman,and Chief Executive Officer of the ... results for this period in a press release to,be ...
... valves years later , , FRIDAY, Nov. 7 (HealthDay News) -- ... fight obesity has been tied to heart value damage that ... new study reports. , The appetite suppressant fenfluramine has ... its links to heart damage. Thousands of lawsuits have been ...
... (NYSE: PER ) ( http://www.perotsystems.com ) today ... 2007, will fully transition its,name to Perot Systems, ... will now refer to the group as the ... the global information,technology provider,s deep healthcare solutions expertise ...
... and ST. PAUL, Minn., Nov. 7 Elementary,school ... bread products,are gradually introduced into their school lunches, ... grain breads are strongly recommended as part of ... eat them. For this study,researchers from the university,s ...
Cached Medicine News:Health News:Barry Manilow Brings Valentine's and Music to New York With Concert to Raise Funds for Breast Cancer Research 2Health News:U.S. Preventive Medicine(R) Awards Inaugural Global Prevention Prize to Dr. Valentin Fuster of Mount Sinai Heart 2Health News:U.S. Preventive Medicine(R) Awards Inaugural Global Prevention Prize to Dr. Valentin Fuster of Mount Sinai Heart 3Health News:Transition Therapeutics to Hold Conference Call on First Quarter Fiscal 2009 Financial Results on Monday, November 10th, at 4:30 P.M. EST 2Health News:Banned Obesity Drug Tied to Heart Risks Long After Use 2Health News:Perot Systems Announces Name Change of JJWild 2Health News:Perot Systems Announces Name Change of JJWild 3
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
Medicine Products: